Compare CDXS & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDXS | MSLE |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.8M | 146.9M |
| IPO Year | 2008 | N/A |
| Metric | CDXS | MSLE |
|---|---|---|
| Price | $2.58 | $8.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 88.1K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $138,590,000.00 | N/A |
| Revenue This Year | $7.73 | N/A |
| Revenue Next Year | $14.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.30 | N/A |
| 52 Week Low | $0.96 | $5.50 |
| 52 Week High | $3.87 | $13.39 |
| Indicator | CDXS | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 76.54 | 60.42 |
| Support Level | $2.37 | $6.67 |
| Resistance Level | $2.86 | $11.98 |
| Average True Range (ATR) | 0.18 | 0.72 |
| MACD | 0.06 | 0.45 |
| Stochastic Oscillator | 85.20 | 79.25 |
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.